Repeated infections after scheduled knee operations in a Tennessee-based facility have culminated into litigation, which prompts critical conversations about the methods and timelines with which medical institutions detect outbreaks. As genomic surveillance becomes a growing force in infection prevention, there are concerns about its potential to inflate legal risks. However, the nuanced reality is that it possibly represents hospitals’ most potent legal defense.
This discourse explores a series of infection at Parkwest Surgery Center, Knoxville, Tennessee, in 2023 where patients’ operations led to persistent infections by Mycobacterium fortuitum, an NTM often associated with surgical settings. This outbreak now catalyzes active litigation, with allegations that the center breached infection control protocols and perpetuated its operations amidst signs of sustained transmission. Such real-life cases illuminate the overarching challenge: how hospitals can promptly detect and address outbreaks to minimize comprehensive harm and avoid legal traps?
Pathogen genomics provides a potent answer to this conundrum. By scrutinizing and comparing pathogen genomes, it assists in detecting transmission events efficiently and early. Questions arise about whether increased outbreak detection could lead to more lawsuits. But the revelation is, if measures are put into action, genomic surveillance can serve as a robust legal shield.
Genomics aids in establishing a direct nexus between a hospital’s circumstances and a patient’s infection, which has historically proven arduous in court cases. By permitting comparisons of genomes from patients, equipment, or the environment, genomics helps to ascertain infections’ likely origination from a common source, thus providing irrefutable evidence to support or refute allegations of nosocomial transmission. Genomic surveillance, however, does not translate into negligence; rather, negligence arises from inactivity, not detection.
Rapid response to an outbreak detected through genomics—such as enhancing cleaning, auditing the practice, and alerting stakeholders—is what any competent infection preventionist should do. Genomics should be seen as a risk mitigation tool, providing early warning and precise intervention targets, charting an evidence trail to demonstrate due diligence if a legal case ever ensues. The implementation of genomic surveillance is still not a defined norm care in the US, but we are witnessing a shift in that direction.
The general apprehension amongst hospitals rests on a common misconception that the detection of more cases implies a worsening scenario. Indeed, this phenomenon is contrary to the truth. Traditional infection prevention methods fail to catch many outbreaks, but genomics brings these invisible issues to the forefront. Genomic surveillance should be envisaged not as a creator of issues, but as a tool to detect overlooked problems.
Complementing robust infection control and prevention protocols, it integrates into the patient safety ecosystem. Infection preventionists must notice that genomics is not a liability. Instead, it increases their expertise, helping reduce harm, enhance safety, and respond effectively to threats. Transparency, preparedness and being proactive, rather than reactive, remain superior legal defense mechanisms.